Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Published:2020-08-13 Issue: Volume: Page:
ISSN:
Container-title:Tumor Biology
language:
Short-container-title:

Author:

Sweeney Christopher J.,Gillessen Silke,Rathkopf Dana,Matsubara Nobuaki,Drake Charles,Fizazi Karim,Piulats Josep M.,Wysocki Piotr J.,Buchschacher Gary L.,Doss Jennifer,Mariathasan Sanjeev,Kadel Edward E.,Yuen Kobe,Datye Asim,Rasuo Grozdana,Tayama Darren,Williams Patrick,Powles Thomas

Publisher

American Association for Cancer Research

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy;Journal of Oncology Pharmacy Practice;2024-07-26

2. Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer;Cancer Immunology Research;2024-03-29

3. Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges;Cancers;2023-05-23

4. Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer;The Oncologist;2023-05-03

5. Emerging treatment options for prostate cancer;Expert Review of Anticancer Therapy;2023-05-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP